A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies
Status:
Completed
Trial end date:
2021-06-25
Target enrollment:
Participant gender:
Summary
This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the
safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of
etrumadenant (AB928) in combination with mFOLFOX in participants with advanced metastatic
gastroesophageal Cancer (GEC) or colorectal cancer (CRC).